武田制药 TAK

Milano Furuta has been Takeda's Chief Financial Officer since April 2024. He was appointed as a Director in June 2024. Mr. Furuta joined Takeda in 2010 and has worked on various projects in corporate strategy, corporate development, and post-merger integration in Japan and Switzerland. He managed the Diabetes Business Unit in Mexico and served as General Manager in Sweden. He went on to serve as Corporate Strategy Officer and Chief of Staff in Japan for two years and President, Japan Pharma Business Unit for three years before his appointment to CFO. Prior to joining Takeda, Mr. Furuta worked as an equity research analyst at Taiyo Pacific Partners L.P. in the United States. He began his career in banking and private equity investment at The Industrial Bank of Japan, Limited (currently Mizuho Financial Group, Inc.) in Japan, where he was involved with several types of financial transactions, including leveraged buyouts and debt restructuring.

Masami Iijima served as External Director who is a member of the Audit and Supervisory Committee of Takeda from June 2021 to June 2022, and was appointed External Director of Takeda and Chair of the Board of Directors in June 2022. Mr. Iijima currently also serves as Executive Advisor of Mitsui & Co., Ltd., External Director of SoftBank Group Corp., Counsellor at Bank of Japan and External Director of Kajima Corporation. Mr. Iijima started his career at Mitsui & Co., Ltd. in April 1974. At Mitsui & Co., Ltd., he served in several senior leadership positions including Chairman of the Board of Directors and Representative Director, President and Chief Executive Officer.

Kimberly A. Reed was appointed External Director who is a member of the Audit and Supervisory Committee of Takeda in June 2022. She currently also serves as Distinguished Fellow of Council on Competitiveness, External Director of Momentus, Inc. and External Director of Hannon Armstrong Sustainable Infrastructure Capital, Inc. Ms. Reed previously served as Counsel for United States House of Representatives, Senior Advisor to United States Secretaries of the Treasury, Director and Chief Executive Officer of Community Development Financial Institutions Fund, Vice President, Financial Markets Policy Relations of Lehman Brothers, President of International Food Information Council Foundation, and Chairman of the Board of Directors, President, and Chief Executive Officer of Export-Import Bank of the United States.

Miki Tsusaka was appointed External Director of Takeda in June 2023. She currently also serves as President of Microsoft Japan Co., Ltd. Prior to joining Microsoft Japan, she was a Senior Partner and Managing Director at Boston Consulting Group (BCG). She established strategic consulting groups specializing in marketing, sales and pricing strategy development and led the expansion of BCG's service areas. As for BCG's operation, she was a member of the Executive Committee for two three-year terms and served as Chief Marketing Officer (CMO) as well.

Steven Gillis has been an External Director with Takeda since January 2019. Prior to his appointment, he was an External Director of Shire plc. He also currently holds the positions of Managing Director at ARCH Venture Partners and serves as a director of private biotechnology companies, including eGenesis, Walden Biosciences, HiberCell, Lifordi Immunotherapeutics and Sonothera. Dr. Gillis previously served as External Director and Chairman at Codiak BioSciences, Inc. and VBI Vaccines, Inc. He was a founder and Director of Corixa Corporation, acquired by GlaxoSmithKline in 2005, and before that a founder and Director of Immunex Corporation.

John Maraganore was appointed External Director of Takeda in June 2022. He is the Principal and CEO of JMM Innovations, LLC., and the Co-CEO of privately held Corsera Health, Inc. He currently also holds External Directorships at Beam Therapeutics, Inc., and Kymera Therapeutics, Inc. and Rapport Therapeutics, Inc. He previously served as Director and CEO of Alnylam Pharmaceuticals, Inc., Senior Vice President and Strategic Product Development at Millennium Pharmaceuticals, Inc., External Director at ProKidney Corporation and Chairperson of Biotechnology Innovation Organization.

Andrew S. Plump, M.D., Ph.D., is the President of Research and Development at Takeda. Dr. Plump joined Takeda as Chief Medical and Scientific Officer (CMSO) in 2015. In his position, he leads our global research and development organization, where he provides strategic direction and oversight. Prior to joining Takeda, Dr. Plump served as Senior Vice President, Research and Translational Medicine, Deputy to the President of research and development at Sanofi, where he was responsible for global research and translational medicine across all therapeutic areas. Dr. Plump also spent more than 10 years at Merck in a Clinical Pharmacology group, working on programs in neurodegeneration, immunology, metabolism and infectious diseases.

Julie Kim is CEO-Elect and a member of Takeda Executive Team of Takeda Pharmaceutical Company Limited. Ms. Kim joined Takeda in 2019 through the acquisition of Shire and has held several diverse roles with increasing responsibility, including President of Plasma-Derived Therapies Business Unit and President of U.S. Business Unit. With three decades of experience working in health care and leadership positions at the global, regional, country and functional levels, Ms. Kim's experiences have spanned a variety of therapeutic areas, international market access, country and regional general management, marketing and emerging market development. Ms. Kim is known for a strong, collaborative and inclusive leadership style that enables Takeda to meet the needs of the people Takeda serves while driving innovations that will improve patients' lives. Her global outlook, a result of having worked in many countries in Europe, Asia and Latin America, as well as having lived in the U.K., Switzerland and the U.S., has helped her foster diverse teams to enable inclusive decision-making that keeps the patient at the center. A committed community leader, she participated in the Massachusetts Governor's Economic Development Planning Council in 2023 as the lead for the Life Sciences working group and will serve on the Governor's newly created advisory commission for the Discovery, Research, and Innovation for a Vibrant Economy (DRIVE) initiative to advise on ways to strengthen the Massachusetts research and innovation ecosystem. She was appointed by the Mayor of Boston to the Board of Trustees of the Boston Public Library, one of the most iconic and respected institutions in the city. She also serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA) and is a member of the Council of Korean Americans. Ms. Kim earned an MBA from the J. L. Kellogg Graduate School of Management at Northwestern University and a bachelor's degree in economics from Dartmouth College. On January 30, 2025, our Board of Directors unanimously resolved to appoint Ms. Kim as the successor to Christophe Weber, President, Chief Executive Officer (CEO) and Representative Director, upon Mr. Weber's retirement from Takeda, expected in June 2026. Ms. Kim has been proposed as a candidate for election to our Board of Directors at the annual general meeting of shareholders to be held in June 2026.

Lauren Duprey is Chief Transformation Officer of Takeda Pharmaceutical Company Limited with responsibility for connecting transformation across the Company, including AI initiatives. She previously served as Takeda's Chief Human Resources (HR) Officer and Head of HR for the U.S. Business Unit. Since joining Takeda, Ms. Duprey has implemented a transformation of HR, including a new operating model, structure, capabilities and technology. Prior to joining Takeda, Ms. Duprey served as Head of HR, U.S. Organization & Worldwide Medical at Biogen where she developed and drove the talent and organization strategy and served as a trusted advisor for key business, talent and organizational decisions. She has held various HR roles at companies such as General Electric and began her career in management consulting at Clarion Healthcare focusing on biopharma commercialization. Ms. Duprey holds a bachelor's degree in biology from Harvard University and an MBA from Massachusetts Institute of Technology (MIT) Sloan School of Management.

Gabriele Ricci is Chief Data and Technology Officer of Takeda Pharmaceutical Company Limited. He was appointed to this role in February 2022 and leads the transformation of Takeda's Data, Digital and Technology division. Mr. Ricci joined Takeda in 2019 as Head of Plasma-Derived Therapies IT, during which he drove initiatives to meet the large and growing demand for plasma-derived products, with highly specialized services that require strategic capacity, innovative business models, dedicated R&D and agile supply allocation on a global scale. Prior to joining Takeda, Mr. Ricci served as Head of Digital Health and Emerging Technology at Shire, where he leveraged new and emerging technologies to optimize internal operations and deliver differentiated patient and customer experiences. Mr. Ricci has also served as Shire's Head of Technical Operations IT and held leadership positions at Novartis, Johnson & Johnson and Bristol-Myers Squibb. Mr. Ricci brings more than 20 years of information technology and engineering expertise in the life sciences industry and sits on several advisory boards for non-profit organizations focused on digital, life sciences and manufacturing. Mr. Ricci holds an MBA from the MIB Trieste School of Management and a bachelor's degree in engineering from the University of Rome Tor Vergata.

Giles Platford is President of International Business Unit of Takeda Pharmaceutical Company Limited, where he directly oversees all markets outside of the U.S., to better position the company for long-term growth and to maximize the patient impact of Takeda's current and future portfolio across diverse international markets. Mr. Platford joined Takeda in 2009 as General Manager of Brazil, and later took on the role of Area Head for the Middle East, Turkey & Africa. He then joined the Takeda Executive Team in 2014 as President of Emerging Markets. In 2017, he became President of Europe & Canada, where he also represented Takeda as a board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). In 2022, he became President of the Plasma-Derived Therapies Business Unit, where he also represented the company as chair of the global executive board for the Plasma Protein Therapeutics Association. He also serves as a board member of the Healthcare Businesswomen's Association. Prior to joining Takeda, Mr. Platford spent eight years in Asia Pacific, where he held a number of roles of increasing responsibility in Business Development, Commercial and General Management. Mr. Platford holds a Bachelor of Arts degree in business and marketing management from Oxford Brookes University, UK, and is currently based in Boston, U.S.

Natalie Furney is Global General Counsel and a member of Takeda Executive Team of Takeda Pharmaceutical Company Limited. Ms. Furney joined Takeda in April 2025. Before joining Takeda, she held various strategic leadership roles at Eli Lilly and Company, most recently as senior vice president and deputy general counsel, where she provided strategic legal counsel to the International Business Unit and Regulatory leadership teams. She also partnered with Ethics & Compliance, HR and Finance to enhance risk mitigation strategies and led the International Legal and Regulatory Legal teams, developing talent and driving organizational excellence. Ms. Furney's 14-year career at Lilly included transforming the Litigation, Investigations and HR Legal teams, as well as leading cross-functional issue management teams in crisis situations. Her leadership resulted in best-in-class legal strategies for the organization. Ms. Furney holds a Juris Doctor degree from Valparaiso University School of Law and a bachelor's degree in journalism and political science from Indiana University - Bloomington. She is admitted to the Indiana Bar and the United States District Court, Southern District of Indiana.

Marcello Agosti is Interim Head of Strategy and Portfolio Development for Takeda Pharmaceutical Company Limited and is responsible for Takeda's business development activities, including M&A and Corporate Development. Mr. Agosti led the Shire acquisition and several other strategic acquisitions for Takeda, including ARIAD Pharmaceuticals, and TiGenix as well as asset acquisitions such as TAK-279 from Nimbus Therapeutics and fruquintinib from HUTCHMED. He also spearheaded a number of strategic divestments of non-core assets as part of Takeda's commitment after the Shire acquisition. Mr. Agosti and his group continue to be active on inbound transactions in Takeda's core therapy areas. Prior to joining Takeda, Mr. Agosti worked in business development at Novartis in the U.K. and Switzerland. Before joining the pharmaceutical industry, he was a consultant at McKinsey & Company. He holds an MBA from the University of Oxford and a business administration degree from Bocconi University, Milan.

Jennifer Smoter is Chief Communications & Governance Officer of Takeda Pharmaceutical Company Limited, leading a centralized Global Communications & Governance organization covering internal and external communications, brand leadership, a governance center of excellence, sustainability, and CEO Chief of Staff responsibilities. Jennifer is responsible for safeguarding Takeda's brand and reputation, deepening trust with stakeholders, and helping shape the external environment in support of Takeda's strategy. She also ensures strong corporate governance, including close coordination with Takeda's Board of Directors. Ms. Smoter joined Takeda in 2026 and has brought nearly three decades of diverse experience in communications, corporate affairs, brand and community and social responsibility. Most recently, Jennifer served as chief communications officer at UnitedHealth Group, where she led a team through advancing Takeda's reputation and navigating complex challenges. Previously, she served as chief external affairs officer at Intellia Therapeutics and held numerous senior communications and brand roles at AbbVie and Abbott Laboratories. Ms. Smoter holds a bachelor's degree from Alverno College and was inducted into the PR Week Hall of Fame in 2024. She is a World 50 Communications member, an Arthur W. Page Society for Communications Professionals seminarian. Jennifer sits on the advisory board of Reversal Therapeutics.

Nicola Greenway is Chief Human Resources (HR) Officer of Takeda Pharmaceutical Company Limited with responsibility for delivering an exceptional people experience across the globe. She joined Takeda in 2012 and has served as Head of HR for the Global Portfolio Division, Head of HR for Global Manufacturing Supply and Quality, Head of HR for the Middle East, Turkey and Africa and Global Head of Talent Development and Organizational Effectiveness. Ms. Greenway brings more than 25 years of global experience in HR spanning leadership roles at KPMG and HSBC. Originally from the Caribbean, she has lived and worked in Dubai, London and Zurich. Ms. Greenway is a passionate mentor and coach, with a deep commitment to diversity, equity and inclusion. She was an executive sponsor of Takeda's Gender Parity Network and represents Takeda on the Healthcare Businesswomen's Association Global Board of Directors, serving as chair of the Board. Ms. Greenway holds a Bachelor of Science and a Master of Science degree, a Master of Arts in business and management, a master's degree in employment law from the University of Surrey, and an executive MBA from ENPC, Paris and the University of Edinburgh.

Bruce Broussard is a candidate for an External Director who is an Audit and Supervisory Committee Member to be appointed in June 2026. He currently also serves as Interim Chief Executive Officer at HP Inc. and External Director at March & McLennan Companies, Inc. Mr. Broussard previously served as Founder and Chief Executive Officer at Harbor Dental, President of Specialty Pharmacy Division at McKesson Corporation and President and Chief Executive Officer at Humana Inc. He has also held several leadership positions at US Oncology, Inc., including Chief Financial Officer, President, Chief Executive Officer and Chairman.

Rhonda Pacheco is President of Takeda's U.S. Business Unit and U.S. Country Head, and a member of Takeda's Executive Team. She leads a portfolio spanning gastroenterology, neuroscience, plasma-derived therapies and rare diseases, driving Takeda's largest market in alignment with the company's global strategy. A Pharmaceutical Doctor and business leader with more than 20 years of experience across multiple countries and roles, Dr. Pacheco brings strategic acumen, operational excellence and people-first leadership. She joined Takeda from Eli Lilly, where she served as Group Vice President of U.S. Cardiometabolic Health. In that role, she built high-performing teams focused on improving patient outcomes, advancing health equity and expanding access to life-changing medicines. She also oversaw complex portfolios and product launches, including Lilly's GLP-1 portfolio, delivering strong commercial results. Dr. Pacheco is passionate about uniting diverse teams around a shared purpose. Her leadership aligns with Takeda's values, purpose and vision, fostering teams that deliver meaningful impact for patients, partners and communities. A Massachusetts native, Dr. Pacheco holds an MBA from Duke University's Fuqua School of Business and a Doctor of Pharmacy from the University of Rhode Island.